Research

Hormonal

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

GoodSupportsHIGH confidence
GLP-1 RAs, particularly semaglutide, similarly deliver significant weight loss (10–15% over 1–2 years) and metabolic benefits. While there is limited data specifically targeting PCOS, emerging studies suggest GLP-1 RAs can improve weight, insulin sensitivity, and menstrual regularity in this group.
Michail Diakosavvas et al. · Current Obesity Reports · 2025

Why this rating

Multiple studies in PCOS specifically (STEP extensions, 2023/2024 studies) show efficacy, though sample sizes are small.

Source

Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome

Michail Diakosavvas et al. · Current Obesity Reports · 2025

DOI 10.1007/s13679-025-00614-2

narrative_reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →